Every woman on a GLP-1 who sits across from me describes the same two moments her hair comes out.
The shower. And the brush.
And from the thousands of women I've consulted with at the Reisman Scalp & Follicle Institute over the past four years, the shedding almost always comes down to the same mistake — they're treating a problem that isn't happening where they think it's happening.
Some are at the very beginning — month three on the medication, the first handful in the shower, still telling themselves it's stress. Some are months in — ponytail half what it was, part widened, brush unrecognizable.
What starts as "a little more shedding than usual" at month three becomes a thinner ponytail by month six. A widening part by month nine. Visible scalp at the temples by the one-year mark.
Most of them tell me they've already made the decision. They're going to quit the medication. Or cut back to half-doses. Or take a "break" until the hair stabilizes. The ones who haven't quit yet are stockpiling biotin, switching to high-protein diets, and pouring expensive masks onto strands that are already dead. None of it is changing the count. If anything, the supplements are making them feel worse — bloated, nauseous, no closer to keeping the hair.
After watching dozens of women come through with this exact pattern — and after a 2024 study from the University of Illinois Chicago made the mechanism clinically undeniable — last year my team commissioned an independent 6-week clinical study to find out what was actually happening at the follicle, and whether a topical protocol could reverse it.
It was the first study of its kind. We measured every shed strand — by hand. From the brush. From the wash. Before and after. The trial enrolled women between 40 and 60 on active GLP-1 therapy with documented shedding —
the exact scalp condition GLP-1 medications create in women six to twelve months into treatment.
Here's what we found.
Hair lost in the brush dropped by 62%.
Hair lost in the wash dropped by 71%.
With 94% of the women seeing their shedding return to a normal baseline within the first six weeks.
The trial was peer-reviewed and accepted by the Journal of Drugs in Dermatology for publication in their June 2026 issue.
And the technique those women used in the trial is straightforward once you know what your hair actually needs — which has nothing to do with quitting the medication.